locanabio.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $318MM
Locanabio develops a new class of genetic medicines that deliver RNA binding protein-based systems to correct the message of disease-causing RNA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
12/14/2020 | Series B | $100MM | $xx.xx | $317.84MM | Acuta Capital Partners, Arch Venture Partners, Gv, Invus, Lightstone Ventures, Ra Capital Management, Temasek, Ucb Ventures, Vida Ventures | |
Price per Share
$xx.xx
Shares Outstanding
22,615,778
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Acuta Capital Partners, Arch Venture Partners, Gv, Invus, Lightstone Ventures, Ra Capital Management, Temasek, Ucb Ventures, Vida Ventures
|
||||||
05/22/2019 | Series A | $55MM | $xx.xx | $79.28MM | Arch Venture Partners, Gv, Lightstone Ventures, Temasek, Ucb Ventures | |
Price per Share
$xx.xx
Shares Outstanding
27,412,278
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Gv, Lightstone Ventures, Temasek, Ucb Ventures
|
||||||
10/31/2017 | Series Seed | $4MM | $xx.xx | $8MM | Arch Venture Partners, Lightstone Ventures, Temasek | |
Price per Share
$xx.xx
Shares Outstanding
4,198,152
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Lightstone Ventures, Temasek
|